Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

  • Bodoor, Khaldon ;
  • Matalka, Ismail ;
  • Hayajneh, Rami ;
  • Haddad, Yazan ;
  • Gharaibeh, Waleed
  • Published : 2012.07.31


The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes - germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.


Diffuse large B-cell lymphoma;immunohistochemistry;BCL 6;CD10;CD138;MUM 1;prognosis


  1. Alizadeh AA, Eisen MB, Davis RE, et al (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-11.
  2. Barrans SL, O'Connor SJ, Evans PA, et al (2002). Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol, 117, 322-32.
  3. Berglund M, Thunberg U, Amini RM, et al (2005). Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol, 18, 1113-20.
  4. Braaten KM, Betensky RA, De Leval L, et al (2003). BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res, 9, 1063-9.
  5. Breslow N A (1970). Generalized kruskal-wallis test for comparing K samples subject to unequal pattern of censorship. Biometrika, 57, 579-94.
  6. Camilleri-Broet S, Criniere E, Broet P, et al (2006). A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood, 107, 190-6.
  7. Chang CC, McClintock S, Cleveland RP, et al (2004). Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 28, 464-70.
  8. Coiffier B, Lepage E, Briere J, et al (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, 235-42.
  9. Colomo L, Lopez-Guillermo A, Perales M, et al (2003). Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, 78-84.
  10. De Paepe P, De Wolf-Peeters C (2007). Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia, 21, 37-43.
  11. Dogan A, Bagdi E, Munson P, et al (2000). CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 24, 846-52.
  12. Fabiani B, Delmer A, Lepage E, et al (2004). CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch, 445, 545-51.
  13. Groves FD, Linet MS, Travis LB, et al (2000). Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst, 92, 1240-51.
  14. Haarer CF, Roberts RA, Frutiger YM, et al (2006). Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med, 130, 1819-24.
  15. Haddadin WJ (2005). Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med, 25, 398-403.
  16. Hallermann C, Niermann C, Fischer RJ, et al (2007). New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. J Am Acad Dermatol, 56, 588-97.
  17. Hans CP, Weisenburger DD, Greiner TC, et al (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-82.
  18. Harada S, Suzuki R, Uehira K, et al (1999). Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia, 13, 1441-7.
  19. Harris NL, Jaffe ES, Stein H, et al (1994). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-92.
  20. Hoffmann C, Tiemann M, Schrader C, et al (2005). AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood, 106, 1762-9.
  21. Hunt KE, Reichard KK (2008). Diffuse large B-cell lymphoma. Arch Pathol Lab Med, 132, 118-24.
  22. Jourdan M, Ferlin M, Legouffe E, et al (1998). The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol, 100, 637-46.
  23. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Amer Statist Assoc, 53, 457-81.
  24. Kojima Y, Tsurumi H, Goto N, et al (2006). Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol, 76, 465-72.
  25. Lin CH, Kuo KT, Chuang SS, et al (2006). Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res, 12, 1152-6.
  26. Linderoth J, Jerkeman M, Cavallin-Stahl E, et al (2003). Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res, 9, 722-8.
  27. Liu YH, Xu FP, Zhuang HG, et al (2008). Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 39, 875-84.
  28. Lopez Guillermo A, Montserrat E (1992). Large-cell lymphomas: the International Prognostic Index. Sangre (Barc), 37, 329-30.
  29. Lossos IS, Jones CD, Warnke R, et al (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood, 98, 945-51.
  30. Lossos IS, Levy R (2003). Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol, 77, 321-9.
  31. Lossos IS, Morgensztern D (2006). Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol, 24, 995-1007.
  32. Magomedova AU, Vorob'ev AI (2008). International prognostic index in diffuse B large cell lymphosarcoma. Ter Arkh, 80, 71-6.
  33. Mann HB, Whitney DR (1947). On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics, 18, 50-60.
  34. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70.
  35. Muris JJ, Meijer CJ, Vos W, et al (2006). Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, 714-23.
  36. Oh YH, Park CK (2006). Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci, 21, 397-405.
  37. Ohshima K, Kawasaki C, Muta H, et al (2001). CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology, 39, 156-62.
  38. Phan RT, Dalla-Favera R (2004). The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature, 432, 635-9.
  39. Pileri SA, Dirnhofer S, Went P, et al (2002). Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 41, 482-509.
  40. Pileri SA, Gaidano G, Zinzani PL, et al (2003). Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol, 162, 243-53.
  41. Saez AI, Saez AJ, Artiga MJ, et al (2004). Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol, 164, 613-22.
  42. Sjo LD, Poulsen CB, Hansen M, et al (2007). Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol, 79, 501-7.
  43. Tsuboi K, Iida S, Inagaki H, et al (2000). MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia, 14, 449-56.
  44. Tzankov A, Pehrs AC, Zimpfer A, et al (2003). Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol, 56, 747-52.
  45. Uherova P, Ross CW, Schnitzer B, et al (2001). The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol, 115, 582-8.
  46. Winter JN, Weller EA, Horning SJ, et al (2006). Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 4207-13.
  47. Wright G, Tan B, Rosenwald A, et al (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A, 100, 9991-6.
  48. Xu Y, McKenna RW, Molberg KH, et al (2001). Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol, 116, 183-90.
  49. Zinzani PL, Dirnhofer S, Sabattini E, et al (2005). Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 90, 341-7.

Cited by

  1. Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases vol.14, pp.2, 2013,
  2. Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B cell Lymphoma and their Correlations with Staging and Prognosis in Iran vol.16, pp.1, 2015,
  3. Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours vol.15, pp.3, 2016,
  4. Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs—syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin’s lymphoma vol.37, pp.9, 2016,
  5. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles vol.5, pp.5, 2016,
  6. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer vol.9, pp.1, 2016,
  7. Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma vol.129, pp.11-12, 2017,
  8. High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms vol.184, pp.2, 2018,